Perioperative Eltrombopag in Patients With Inherited Thrombocytopenia

Thrombocytopenia Clinical Trial

— ELPOT  

Official title:

Evaluation of Perioperative Eltrombopag for the Management of Elective Surgery and Invasive Acts in Patients With Inherited Thrombocytopenia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03638817
• Other study ID #: RC31/16/8913
• Secondary ID: 2017-004489-88
• Status: Recruiting
• Phase: Phase 2
• Start date: August 2, 2019
• Est. completion date: December 2023

Study information

• Verified date: January 2023
• Source: University Hospital, Toulouse
• Contact: Pierre SIE, Prof.
• Phone: 561322289
• Email: sie.p[@]chu-toulouse.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the study is to estimate the response to eltrombopag based on platelet count increase above a safety level of 80 G/L and lack of requirement for pre-, per- and post-operative administration of platelet concentrates (PC) for performing elective invasive acts at mild or high bleeding risk,in selected patients with inherited thrombocytopenia (IT).

Description:

The hypothesis of the trial is that preoperative treatment by a thrombopoietin mimetic (eltrombopag) will be effective and safe and will avoid requirement of PC administration in a majority of IT patients Eltrombopag is a thrombopoietin mimetic available orally, not licenced for the treatment of IT. Preliminary data in short series of IT patients indicate that eltrombopag, at the doses used in primary immune thrombocytopenia, increases the platelet counts after 2-4 weeks of treatment and reduces spontaneous bleeding in a significant proportion of subjects. The tolerance of short-term treatment is good. The experience of eltrombopag for the management of perioperative thrombocytopenia in IT is anecdotic. Avoiding the administration of platelet concentrates in these patients, especially children, would represent a direct benefit by preventing adverse reactions to transfusion of blood products and human leukocyte antigen (HLA) immunisation.

Eltrombopag will be prescribed after the inclusion visit at the standard dose of 50 mg/day with dose adjustment on the platelet count (+/- 25 mg) after 2 weeks, for a maximum of 4 weeks before the invasive procedure. If the predefined safety level of platelet count required for the procedure is reached, the treatment will be discontinued and the patient operated without prophylactic administration of PC. In case of bleeding of undetermined cause per-and post-operatively, rescue PC will be given.

Clinical and biological follow-up will be performed until the end-of-study visit, 4 weeks after the intake of the last tablet of eltrombopag.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 75 Years

Eligibility

Inclusion Criteria:

• Symptomatic patients with bleeding history and chronic thrombocytopenia with strong presumption of constitutional origin on the basis of

• the identified mutation and/or

• a combination of the following criteria: familial antecedent with Mendelian transmission, duration of thrombocytopenia, suggestive syndromic presentation, and evidence against primary or secondary immune thrombocytopenia, especially absence of immunologic markers and failure of previous conventional or immunosuppressive therapies.

• Averaged platelet counts during the last five years below the safety level required for the procedure.

• Scheduled (>4 weeks) surgery or invasive procedure with anticipated risk of bleeding:

e.g. needle biopsy of solid organ (liver, kidney….etc.), interventional endoscopy, major surgeries, or surgery without possibility of mechanical control of haemostasis (e.g. tonsillectomy). Written informed consent of the patient or his (her) parents or tutors (patients < 18 yrs).

Patients included in the French national registry of rare platelet disorders

• Patient with social insurance coverage

Exclusion Criteria:

• questionable constitutional origin;

• definite platelet dysfunction associated to thrombocytopenia (eg: gray platelet syndrome, NBEAL2 and related gene mutations, homozygous Bernard-Soulier Syndrome);

• thrombocytopenia with predisposition to hematologic malignancies (e.g; RUNX1, ETV6 or ANKRD26 gene mutations).

• amegakaryocytic thrombocytopenia resulting from mutations in the thrombopoietin (TPO) TPO-Mpl receptor, supposed, by definition, to be hardly responsive to receptor agonists.

• questionable requirement of prophylactic PC transfusions;

• procedure usually associated with platelet consumption requiring transfusions of PC (e.g.: cardiac surgery), making difficult the evaluation of success or failure;

• procedures at risk of bleeding with immediate vital or functional consequences (e.g.:

intra cranial surgery);

• personal history of arterial or venous thromboembolic events or known familial thrombophilia;

• association with another acquired or constitutional hemorrhagic diathesis;

• chronic hepatitis, cirrhosis, with moderate to severe liver failure (Child-Pugh score =5);

• previous or concurrent myeloid malignancy, including myelodysplastic syndrome;

• alanine aminotransferase (ALT) or bilirubin levels 2 times the upper limit of normal (ULN);

• altered renal function (creatinin clearance <30 ml/min);

• pregnancy (negative test required before inclusion in fertile women) or lactating women;

• refusal of safe contraception;

• ocular lenses opacity;

• hypersensitivity to eltrombopag or one of excipients;

• previous participation to the present study;

• current treatment with antiplatelet drugs, anticoagulants or direct acting antiviral agents approved for treatment of chronic hepatitis C infection;

• psychiatric, social or behavioral condition judged to be non-compatible with the respect of the protocol, including good observance of treatment and compliance to follow-up;

• adult protected by the law.

Related Conditions & MeSH terms

• Thrombocytopenia

Intervention

Drug:
• Eltrombopag
Eltrombopag will be prescribed at doses recommended in primary immune thrombocytopenia (50, 25 or 75 mg), starting 4 weeks before the procedure and stopped 2 days before. PC will be administrated prophylactically if the platelet count is < 80 G/L or per/post-operatively in case of bleeding of undetermined cause. Antifibrinolytics will be authorized and low molecular weight heparin prescribed if indicated for the prophylaxis of postoperative venous thrombosis according to the standard dose and duration, , irrespective of the platelet count

Locations

Country	Name	City	State
France	Angers Hospital	Angers
France	Bensancon Hospital	Besançon
France	Bordeaux Hospital	Bordeaux
France	Caen Hospital	Caen
France	Clermont-Ferrand Hospital	Clermont-Ferrand
France	Dijon Hospital	Dijon
France	Lille Hospital	Lille
France	Hospices Civils Lyon	Lyon
France	Marseille Hospital	Marseille
France	Montpellier Hospital	Montpellier
France	Nancy Hospital	Nancy
France	Nantes Hospital	Nantes
France	Cochin Hospital	Paris
France	Hopital Europeen G Pompidou	Paris
France	Kremlin Bicetre Hospital	Paris
France	Necker Hospital	Paris
France	Robert Debré Hospital	Paris
France	Trousseau Hospital	Paris
France	Poitiers Hospital	Poitiers
France	Reims Hospital	Reims
France	Rennes Hospital	Rennes
France	Rouen Hospital	Rouen
France	Strasbourg Hospital	Strasbourg
France	university hospital Toulouse	Toulouse
France	Tours Hospital	Tours

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital, Toulouse	French network for inherited hemorragic diseases, National Reference Centre for Platelet Pathologies

Country where clinical trial is conducted

France, 

References & Publications (7)

Favier R, Feriel J, Favier M, Denoyelle F, Martignetti JA. First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia. Pediatrics. 2013 Sep;132(3):e793-5. doi: 10.1542/peds.2012-3807. Epub 2013 Aug 12. — View Citation

Fiore M, Saut N, Alessi MC, Viallard JF. Successful use of eltrombopag for surgical preparation in a patient with ANKRD26-related thrombocytopenia. Platelets. 2016 Dec;27(8):828-829. doi: 10.1080/09537104.2016.1190446. Epub 2016 Jun 8. No abstract available. — View Citation

Gerrits AJ, Leven EA, Frelinger AL 3rd, Brigstocke SL, Berny-Lang MA, Mitchell WB, Revel-Vilk S, Tamary H, Carmichael SL, Barnard MR, Michelson AD, Bussel JB. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood. 2015 Sep 10;126(11):1367-78. doi: 10.1182/blood-2014-09-602573. Epub 2015 Jul 29. — View Citation

Pecci A, Barozzi S, d'Amico S, Balduini CL. Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation. Thromb Haemost. 2012 Jun;107(6):1188-9. doi: 10.1160/TH12-01-0005. Epub 2012 Mar 8. No abstract available. — View Citation

Pecci A, Gresele P, Klersy C, Savoia A, Noris P, Fierro T, Bozzi V, Mezzasoma AM, Melazzini F, Balduini CL. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood. 2010 Dec 23;116(26):5832-7. doi: 10.1182/blood-2010-08-304725. Epub 2010 Sep 15. — View Citation

Pecci A. Pathogenesis and management of inherited thrombocytopenias: rationale for the use of thrombopoietin-receptor agonists. Int J Hematol. 2013 Jul;98(1):34-47. doi: 10.1007/s12185-013-1351-7. Epub 2013 May 1. — View Citation

Zhang J, Liang Y, Ai Y, Xie J, Li Y, Zheng W. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review. Expert Opin Pharmacother. 2017 Oct;18(15):1543-1551. doi: 10.1080/14656566.2017.1373091. Epub 2017 Sep 4. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Perioperative management by eltrombopag in inherited thrombocytopenia	The response to Eltrombopag is a composite criteria including the level of platelet count 2 days before the procedure and the requirement of PC administration at any time in the study period. The "study period" is running from the start of treatment (inclusion visit) to 4 weeks after completion of treatment. A platelet count remaining below 80 G/L preoperatively, whether or not eltrombopag was taken, is a criterion of failure of treatment.	up to 4 weeks after completion of treatment
Secondary	Adverse events	Adverse events and adverse reactions occurring at any time during the study period will be collected. Adverse events may be clinical and biological (especially liver function tests).	up to 4 weeks after completion of treatment
Secondary	Excessive bleeding	Excessive or unusual bleeding occurring at any time during the study period are major adverse events. An independent event adjudication committee (EAC) will review all bleeding events.	up to 4 weeks after completion of treatment
Secondary	Vascular thrombosis	Symptomatic thrombosis (venous or arterial) occurring at any time during the study period will be diagnosed by appropriate objective methods and reviewed by the EAC.	up to 4 weeks after completion of treatment
Secondary	Doses of eltrombopag on-treatment	The total doses of eltrombopag given in the preoperative period will be recorded, as the dose and duration of treatment required to obtained the safety level	2 and 4 weeks after the beginning of the treatment
Secondary	Platelet kinetics	Serial blood sampling during the study period will be performed for measuring the rise of platelet count on-treatment and its decline after completion of treatment.	up to 4 weeks after completion of treatment
Secondary	Platelet size	Mean platelet volume will be measured by flow cytometry.on blood samples obtained for platelet counts at inclusion, during hospitalisation and end-of study visit	Inclusion and before the procedure
Secondary	Baseline of Serum Thrombopoietin	Serum thrombopoietin will be measured once, at the inclusion visit.	Inclusion visit